Literature DB >> 18563337

The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.

Xiaomao Li1, Lan Xiao, Yuebo Yang, Huimin Shen, Haitao Zeng, Zehua Wang.   

Abstract

The activation of mammalian target of rapamycin (mTOR) signaling pathway in endometrial carcinoma cells Ishikawa and HEC-1A was investigated. The expression of mTOR was detected by confocal fluorescence microscopy in Ishikawa and HEC-1A cells. The mRNA levels of PTEN and mTOR, the downstream substrate S6K1 and 4E-BP1 protein were assayed by RT-PCR and Western blot, respectively. The expression of PTEN in Ishikawa cells was deficient, but intact in HEC-1A cells respectively (P<0.01). There was mTOR expression in both Ishikawa and HEC-1A cells and the phosphorylated substrate levels in Ishikawa cells were higher than those in HEC-1A cells (P<0.05). mTOR signaling pathway is activated in two endometrial carcinoma cell strains and the status of activation is related with PTEN expression of the cells. The activation level of mTOR is higher in PTEN-deficient endometrial carcinoma cells than that in PTEN-intact endometrial carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563337     DOI: 10.1007/s11596-008-0325-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

1.  In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.

Authors:  Daisuke Ito; Koji Fujimoto; Tomohiko Mori; Kazuhiro Kami; Masayuki Koizumi; Eiji Toyoda; Yoshiya Kawaguchi; Ryuichiro Doi
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

Review 2.  [Pten gene expression in the endometrial mucosa].

Authors:  Anna Bakiewicz; Jarosław Goździk; Stanisław Sporny
Journal:  Ginekol Pol       Date:  2006-04       Impact factor: 1.232

Review 3.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 4.  The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.

Authors:  Agnieszka Janus; Tadeusz Robak; Piotr Smolewski
Journal:  Cell Mol Biol Lett       Date:  2005       Impact factor: 5.787

5.  The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.

Authors:  Takayuki Asano; Yixin Yao; Jijiang Zhu; Donghui Li; James L Abbruzzese; Shrikanth A Reddy
Journal:  Biochem Biophys Res Commun       Date:  2005-05-27       Impact factor: 3.575

6.  Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.

Authors:  Deborah A Altomare; Huihong You; Guang-Hui Xiao; Maria E Ramos-Nino; Kristine L Skele; Assunta De Rienzo; Suresh C Jhanwar; Brooke T Mossman; Agnes B Kane; Joseph R Testa
Journal:  Oncogene       Date:  2005-09-08       Impact factor: 9.867

7.  mTOR and P70 S6 kinase expression in primary liver neoplasms.

Authors:  Fikret Sahin; Rajesh Kannangai; Onikepe Adegbola; Jianzhou Wang; Gloria Su; Michael Torbenson
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

8.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Authors:  Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 9.  Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor.

Authors:  Anthony W Tolcher
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

10.  Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Authors:  Guang Xu; Wanghai Zhang; Paula Bertram; Xiao Feng Zheng; Howard McLeod
Journal:  Int J Oncol       Date:  2004-04       Impact factor: 5.650

  10 in total
  1 in total

1.  Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.

Authors:  Anna Torres; Kamil Torres; Anna Pesci; Marcello Ceccaroni; Tomasz Paszkowski; Paola Cassandrini; Giuseppe Zamboni; Ryszard Maciejewski
Journal:  BMC Cancer       Date:  2012-08-24       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.